We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
NUVAXOVID-SARS-CoV-2 rS (NVX-CoV2373) (Biocelect Pty Ltd)
Product name
NUVAXOVID-SARS-CoV-2 rS (NVX-CoV2373)
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
61 (255 working days)
Active ingredients
SARS-CoV-2 rS (NVX-CoV2373)
Registration type
EOI
Indication
NUVAXOVID has provisional approval for the indication:
Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 12 years of age and older.
The use of this vaccine should be in accordance with official recommendations.
The decision has been made on the basis of short-term efficacy and safety data. Continued approval depends on the evidence of longer term efficacy and safety from ongoing clinical trials and post-market assessment.
Registration process
Provisional registration
Involves early access to vital and life-saving medicines through time-limited registration